SEC Form 4 · accession 0001562180-19-001423
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith R Leonard
Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2019 | P | 100,000 | $2.50 | A | 100,000 | D | |
| Common StockF2 | holding | — | — | — | 31,784 | I | See Footnote | |
| Common StockF3 | holding | — | — | — | 16,700 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's public offering at the offering price of $2.50 per share.
- F2The shares are directly held by Andalucia Ventures LLC, a limited liability company in which the Report Person holds a controlling interest.
- F3The shares are directly held by the Leonard Family Trust.